SkinBioTherapeutics PLC (SBTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has a cash flow conversion efficiency ratio of -0.053x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-494.84K ≈ $-60.21 USD) by net assets (GBX9.42 Million ≈ $1.15K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SBTX stock market capitalisation for the company's overall valuation and market capitalisation.
SkinBioTherapeutics PLC - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
SkinBioTherapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SkinBioTherapeutics PLC ranked by their cash flow conversion efficiency. Explore earnings quality score of SkinBioTherapeutics PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Checkit PLC
LSE:CKT
|
-0.132x |
|
Kavango Resources PLC
LSE:KAV
|
-0.160x |
|
GETT Gold Inc
V:GETT
|
-0.004x |
|
Provexis plc
LSE:PXS
|
-0.307x |
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
SysGroup PLC
LSE:SYS
|
0.029x |
|
Europa Oil & Gas Holdings
LSE:EOG
|
-0.080x |
|
SCRYB INC.
F:EIY
|
N/A |
Annual Cash Flow Conversion Efficiency for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual cash flow conversion efficiency of SkinBioTherapeutics PLC from 2016 to 2025. View SkinBioTherapeutics PLC (SBTX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | GBX9.42 Million ≈ $1.15K |
GBX-1.30 Million ≈ $-157.94 |
-0.138x | +84.99% |
| 2024-06-30 | GBX2.97 Million ≈ $361.35 |
GBX-2.73 Million ≈ $-331.71 |
-0.918x | +30.77% |
| 2023-06-30 | GBX1.99 Million ≈ $242.72 |
GBX-2.65 Million ≈ $-321.84 |
-1.326x | -22.79% |
| 2022-06-30 | GBX2.48 Million ≈ $301.18 |
GBX-2.67 Million ≈ $-325.23 |
-1.080x | -262.16% |
| 2021-06-30 | GBX5.22 Million ≈ $634.55 |
GBX-1.56 Million ≈ $-189.20 |
-0.298x | +17.59% |
| 2020-06-30 | GBX2.47 Million ≈ $300.02 |
GBX-892.14K ≈ $-108.55 |
-0.362x | +3.51% |
| 2019-06-30 | GBX3.81 Million ≈ $463.58 |
GBX-1.43 Million ≈ $-173.82 |
-0.375x | -93.22% |
| 2018-06-30 | GBX3.44 Million ≈ $418.67 |
GBX-667.75K ≈ $-81.25 |
-0.194x | -34.11% |
| 2017-06-30 | GBX4.21 Million ≈ $512.66 |
GBX-609.70K ≈ $-74.18 |
-0.145x | -4733.88% |
| 2016-06-30 | GBX389.85K ≈ $47.43 |
GBX-1.17K ≈ $-0.14 |
-0.003x | -- |
About SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more